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Abstract 
The poor solubility of significant number of Active Pharmaceutical Ingredients (APIs) has 
become a major challenge in the drug development process. Drugs with poor solubility are 
difficult to formulate by conventional methods and often show poor bioavailability. In the last 
decade, attention has been focused on developing nanocrystals for poorly water soluble drugs 
using nanosizng techniques. Nanosizing is a pharmaceutical process that changes the size of a 
drug to the sub-micron range in an attempt to increase its surface area and consequently its 
dissolution rate and bioavailability. The effectiveness of nanocrystal drugs is evidenced by 
the fact that six FDA approved nanocrystal drugs are already on the market. The 
bioavailabilities of these preparations have been significantly improved compared to their 
conventional dosage forms. There are two main approaches for preparation of drug 
nanocrystals; these are the top-down and bottom-up techniques. Top-down techniques have 
been successfully used in both lab scale and commercial scale manufacture. Bottom-up 
approaches have not yet been used at a commercial level, however, these techniques have 
been found to produce narrow sized distribution nanocrystals using simple methods. Bottom-
up techniques have been also used in combination with top-down processes to produce drug 
nanoparticles. The main aim of this review article is to discuss the various methods for 
nanosizing drugs to improve their bioavailabilities. 
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1. Introduction 
Advancements in combinatorial chemistry, high throughput screening, biology and genomics 
have led to an increase in the number of molecules which can be potential drug candidates. 
However, poor aqueous solubility and bioavailability has led to failure of more than 40 % of 
these molecules during the drug development stages (1-4). Regardless of excellent 
pharmacological activity, many of these Active Pharmaceutical Ingredients (APIs) fall under 
Class II of the Biopharmaceutics Classification System (BCS). The BCS system classifies 
drugs into four categories depending on their aqueous solubility and membrane permeability 
(5). To overcome problems like poor aqueous solubility, the pharmaceutical industry and 
researchers have focused on developing formulation strategies for drugs classified under BCS 
class II (poor solubility and high permeability) and BCS class IV (poor solubility and 
permeability) (2, 5). A large number of approaches have been developed to improve oral 
bioavailability of these compounds by increasing their aqueous solubility and dissolution 
rates.  
Conventional approaches for increasing the dissolution of drugs include formation of salts, 
use of solubilizing agents, complexing agents, etc. Previously, there was considerable 
difficulty with formulating a large number of compounds using conventional approaches. 
Currently, the use of conventional approaches is increasingly limited due to side-effects 
associated with salt formation, addition of co-solvents and requirements of large quantities of 
excipients in the formulation (1, 6). Other methods to improve the bioavailability of drugs 
include microemulsions (7), inclusion of cyclodextrins (8), melt extrusion (9), emulsions 
(10), liposomes (11), and solid dispersions  (2, 6). All these methods have been successfully 
utilized in developing formulations for poorly water soluble drugs, especially for compounds 
which are highly potent. In addition to the above mentioned approaches, methods such as 
particle size reduction to the sub-micron size range, e.g. nanosizing of drug particles or 
nanosuspensions, have gained much attention in recent years (2, 4, 12).  
Nanosizing is defined as a pharmaceutical process that involves reducing the particle size of 
the active pharmaceutical ingredient to the nanometre size range. It means achieving the 
particle size below the sub-micron range i.e. particle size less than 1µm (13). Nanosizing 
techniques have become more popular as they can be applied to most compounds which have 
poor solubility issues. These techniques are referred to as ‘non-specific techniques’ to 
improve the bioavailability of poorly soluble drugs (13-15). According to the Noyes-Whitney 
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equation, a decrease in the particle size of a drug results in an increase in its surface area and 
thus the dissolution rate will increase proportionally which results in better absorption of 
poorly soluble drugs (3, 4, 13). Recent advancements in nanosizing techniques have enabled 
the pharmaceutical industry and researchers to produce particles in the 100-200 nm range in a 
reproducible manner (3).  
There are various approaches for nanosizing drugs and these are classified as top-down, 
bottom-up and combination approaches. Top-down techniques involve particle size reduction 
using high energy approaches such as media milling and high pressure homogenization. 
Currently, there are six FDA approved nanocrystal drugs in the market which have been 
prepared by top-down techniques (16). All these processes are conducted in a liquid medium 
and thus they form nanosuspensions which are later processed into capsules or tablets or 
marketed as suspensions (3, 17).  
Nanosuspensions refer to colloidal dispersions of sub-micron drug particles which are 
stabilized by addition of a suitable polymer or surfactant, and are of a particle size below 
1000 nm (4, 13, 18). The dispersion medium can be aqueous e.g. water, or non-aqueous e.g. 
liquid polyethylene glycol and oils (13). Bottom-up techniques are essentially a precipitation 
technique as the nanosized drug particles are obtained after precipitation from a 
supersaturated drug solution (16). Bottom-up techniques offer many advantages such as being 
low energy processes and less expensive in comparison with other nanosizing methods, and 
produce particles with narrow size distribution. However, very few products prepared by 
bottom-up techniques have made it to market (19). Bottom-up techniques have recently been 
used in combination with top-down techniques to obtain even smaller particles.  
Although these techniques have been in use for at least a decade, very few nanocrystals with 
a particle size of 100 nm have been obtained. Various attempts have been made to develop 
particles of less than 100 nm as it has been reported that drug nanocrystals of less than 100 
nm have novel physical properties and show improvement in permeation through various 
biological barriers (16). Drug nanocrystals have improved the bioavailability of poorly-
soluble drugs that are administered through a variety of routes including oral, dermal, ocular, 
buccal and pulmonary. 
This review article will focus on various techniques for preparation of drug nanocrystals e.g. 
bottom-up techniques, top-down techniques and combination techniques. Case studies will 
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illustrate the ways in which the particle size of certain drugs has been reduced to the sub-
micron range by utilising various nanosizing techniques. 
2. Biopharmaceutical classification system (BCS) 
The BCS is a system which classifies drugs according to their aqueous solubility and 
intestinal permeability. Aqueous solubility correlates with in vitro dissolution and the 
intestinal permeability correlates with in vivo bioavailability of the drug particles (6). 
According to the BCS, a drug is considered highly soluble if the highest strength of the drug 
is soluble in 250 ml of water and it is considered highly permeable if intestinal permeability 
of the drug is 90%. On the basis of BCS, all drugs have been classified into four categories 
i.e. BCS class I, class II, class III and class IV (6). The BCS System classification is shown in 
table 1 below: 
Table 1. BCS Classification (6) 
BCS Class I  
(high solubility and high permeability) 
e.g. Metoprolol, Diltiazem 
BCS Class II 
(low solubility and high permeability) 
e.g. Phenytoin, Danazol 
BCS Class III 
(high solubility and low permeability) 
e.g. Acyclovir, Cimetidine 
BCS Class IV 
(low solubility and low permeability) 
e.g. Furosemide, Hydrochlorothiazide 
 
The drugs in BCS class II and class IV have low solubility, therefore nanosizing of these 
drugs can increase their bioavailability. The BCS classification has been well accepted but a 
revised classification system, known as the Developability Classification System (DCS) has 
recently been introduced to classify drugs in a more relevant manner and it has been 
particularly useful in predicting critical factors related to in vivo performance as compared to 
BCS (20). In some cases it has been found that drugs have such a low aqueous solubility that 
even the nanocrystals of that drug showed very low bioavailability (21). For this reason, DCS 
classifies drugs according to whether they have dissolution rate-limited, solubility-limited or 
permeability-limited bioavailability. The dissolution rate-limited drugs are categorized under 
DCS class IIa and solubility-limited drugs are classified under DCS class IIb. Nanosizing of 
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drugs has been found to be a suitable approach for dissolution-rate limited compounds i.e. 
DCS class IIa (21).  
 
3. Methods of nanosizing: 
As previously described, there are different nanosizing methods and these are classified as 
bottom-up techniques, top-down techniques and combination techniques (4).  
4. Bottom-Up Techniques 
Bottom-up techniques are also referred to as precipitation techniques as nanosized drug 
particles are formed by precipitation which can be in crystalline or amorphous form (13). In 
this method, drug is precipitated from supersaturated drug solution, or by evaporation of 
solvent, or by mixing the drug with a non-solvent (4, 14). These techniques have not gained 
much traction in the pharmaceutical industry due to difficulties in controlling particle growth 
and the process   (21). However, bottom-up techniques are used in combination with top-
down techniques to improve the effectiveness of the method. Some bottom-up technologies 
used are sonocrystallization, confined impinging liquid jet precipitation, high gravity 
controlled precipitation technology, and multi- inlet vortex mixing (13).  
4.1 Precipitation by addition of liquid antisolvent 
Precipitation of a drug from its solution by addition of an antisolvent is an effective method 
of obtaining nanosized particles. Moreover, the size of the particles and morphology of the 
finished product can be controlled (24). In this method, a drug is dissolved in a solvent and 
then mixed with another solvent which is miscible with the first solvent but acts as an 
antisolvent (e.g. water) for the drug (16, 25). This results in increased super-saturation of the 
solution due to diffusion of solvent into the antisolvent and nucleation of the particles. During 
drug precipitation, particle growth and nucleation can compete by a process called “Ostwald 
ripening” but the process should be directed towards nucleation by the use of suitable 
excipients and stabilizers (24, 26).  
This method of obtaining nanosized drug particles is easy and cost-effective as compared to 
other methods of nanosizing (27, 28) and it can be easily scaled up as it does not require any 
expensive equipment (29). There are, however, some critical process parameters that affect 
the particle size and the physicochemical properties of the nanosized drugs such as  the nature 
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and selection of solvent and antisolvent, volume ratio of solvent and antisolvent, and their 
order of addition (16). An antisolvent precipitation technique has been used to prepare drugs 
such as atorvastatin (30), taxifolin (31), amorphous amphotericin B (32), and danazol (33). 
This method of nanosization can be divided into two types i.e. simple mixing and modified 
mixing methods (16).  
4.1.1. Simple mixing method using static mixer 
In this method, nanosized drug particles are produced by mixing the drug solution and 
antisolvent using mixing forces. The solvent plays an important role in production of 
submicron particles as it should solubilize the drug and have a fast diffusion rate towards the 
antisolvent. The solvents used for preparation of drug solution can be organic e.g. ethanol, 
methanol, IPA, NMP, acetone etc., or co-solvents e.g. polyethylene glycol or propylene 
glycol (16, 34). Solvents such as PEGs which are ‘environmentally friendly’ are preferred 
over other organic solvents which are toxic in nature (16). Selection of solvent is based 
primarily on the solubility of drug in the solvent but other factors such as the interaction 
between solvent and stabilizer are considered important (16). Static mixers have been 
described in the literature as ‘simple mixing equipment’ (35, 36). Static mixers offer several 
advantages over other mixing equipment including low cost, low  energy consumption, less 
space required and homogenous mixing of miscible solvents (37). 
Nanomorph® technology for the preparation of nanosupensions was developed by SOLIQS 
(Abbott GmbH & Co., KG, Ludwigshaven, Gemany) and Hydrosols prepared by Sucker 
(Novartis) are examples of antisolvent precipitation techniques (26, 38). These techniques 
can be employed for continuous operations in the pharmaceutical industry instead of batch 
production processing (38). The process of preparing drug nanoparticles by the Nanomorph® 
technique involves dissolving a drug in a suitable organic solvent  then mixing the resultant 
solution with an antisolvent containing stabilizers; this means that precipitation of drug takes 
place in presence of stabilizers (16, 26). Stabilizers or polymers prevent the growth of coarse 
particles or aggregation of particles and help to keep the drug particles in their nanoparticle 
stage (39).  
4.1.2. Modified Mixing Methods 
These methods involve precipitation of drug by additional external features. It has been 
reported, for example, that addition of ultrasonic waves or alteration in the environment of 
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precipitation e.g. freeze drying, spray drying or high gravity precipitation, may produce 
smaller particles compared to conventional methods (16). 
4.1.2.1. Sonoprecipitation 
Ultrasonic sound has been used to provide homogenous conditions within the vessel during 
the antisolvent process (40). The principle behind sonoprecipitation is formation of bubbles, a 
process known as cavitation, and simultaneous collapse of these bubbles which releases 
shock waves. The waves result in faster and more uniform nucleation which further results in 
smaller particle size and reduction of agglomeration of particles by controlling the number of 
nuclei (40, 41). The process has been reported to increase micro-mixing and formation of 
amorphous particles with uniform particle size (16, 40). However, the final product particle 
size is dependent on the duration and intensity of sonication, the frequency of ultrasound, 
horn length (16).   
The sonoprecipitation process is very fast and results in homogenous mixing of solvent and 
antisolvent within seconds after the application of ultrasonic sound (40). As the process is 
very fast, less organic solvent is required for antisolvent precipitation (41). The experimental 
set-up for sonoprecipitation is very simple and it consists of  an ultrasonic bath containing  
antisolvent and solvent atomized into the sonicator using compact air pressure (16). 
Sonoprecipitation techniques have been used to prepare cefuroxime axetil nanoparticles with 
a particle size of 130 nm, and it was found that by doubling the amplitude of sonication, 
particle size was further reduced to 80 nm (41). 
4.1.2.2. High gravity controlled precipitation technique (HGCP) 
This technique has been used for the preparation of nanosized inorganic particles e.g. CaCO3 
(15-40 nm) and Al(OH)3 (1-10 nm) (16, 42), and organic particles e.g. salbutamol sulphate, 
ephedrine and benzoic acid (43-45). The drug particles obtained by this method were found 
to have a narrower size distribution and specific morphology and crystal state as compared 
with particles produced by other methods (42). The HGCP technique utilizes a rotating 
packed bed containing packing material made of metal or plastic wire mesh (Figure 1). Two 
liquid streams (reactant A and B) pass via distributors and are mixed at the centre of the 
rotating packed bed where the mixture is subjected to high gravity due to centrifugal forces 
which force the mixture to pass from the packing before leaving the reactor (41).  
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The HGCP technique can be combined with the antisolvent precipitation process and is 
known as the high gravity antisolvent precipitation (HGAP) process (16). This process has 
been used in the preparation of cefuroxime axetil nanoparticles with a mean particle size of 
300nm without using stabilizers. The particles were reported to have a high specific surface 
area which was around four times higher than that of commercial cefuroxime axetil (46). The 
HGAP process has also been utilised to prepare nanoparticles of other pharmaceutical 
ingredients such as danazol with a particle size of about 190 nm (33). Figure 1 shows a 
schematic diagram of high gravity controlled precipitation (HGCP). 
 
Fig. 1.  Schematic diagram of HGCP (41). 
4.2. Supercritical fluid (SCF) technique 
Supercritical fluids have unique physical properties including low density and viscosity and 
have a high diffusion rate which helps to attain rapid mixing for precipitation (41). Carbon 
dioxide (CO2) is the most favourable SCF used for pharmaceutical processing due to its  
almost ambient critical temperature of 31.1°C and pressure of 72.9 atm which allows it to be 
easily converted to a supercritical state (16, 41). Moreover, it is inexpensive, readily available 
and non-toxic. Supercritical fluid techniques that have been used by pharmaceutical 
companies and researchers include rapid expansion of supercritical solution (RESS) and 
supercritical antisolvent (SAS) (16, 41).  
4.2.1. Rapid expansion of supercritical solutions (RESS) 
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This technique has been employed for  drugs which have good solubility in CO2  (47). As 
CO2 has a low polarity, it dissolves hydrophobic drugs to form a solution which rapidly 
expands into a low pressure area through an opening of a narrow nozzle (41). As the solution 
reaches a low pressure area, its density changes which results in supersaturation of the 
solution and thus precipitation of solute (16). One of the major drawbacks of this technique is 
that  many drugs are not soluble in supercritical carbon dioxide and, to overcome this 
problem, a modified process known as rapid expansion of supercritical solution with solid 
(RESS-SC) has been introduced. In the RESS-SC method, a solid co-solvent is added  to 
increase the solubility of the polar compounds (16). The other RESS modified processes are 
rapid expansion of supercritical fluid into a liquid solvent (RESOLV), and rapid expansion 
from supercritical to aqueous solution (RESAS) (16, 47). Table 2 shows examples of 
nanoparticles obtained by RESS and modified RESS techniques. 
Table 2. Summary of nanoparticles obtained by RESS and modified RESS techniques. 
API Method Solvent Operating 
conditions 
Mean 
diameter 
(nm) 
Reference 
Raloxifene RESS CO2 100-180 bar 
40-80°C 
19nm (48) 
Clobetasol 
propionate 
RESS-SC CO2 and 
menthol (co-
solvent) 
200-260 bar  
70-110°C 
95nm-
318.8nm 
(49) 
Theophylline RESS-SC CO2 and 
vanillin (co-
solvent) 
220 bar 
40-70°C 
85nm (50) 
Megestrol 
acetate 
RESS-SC CO2 and 
menthol (co-
solvent) 
150-250 bar 
40-60°C 
102.8-
516.3nm 
(51) 
Retinyl 
palmitate 
poly(L-
lactide) 
RESOLV CO2 330 bar 
70-100°C 
 
40-110nm (52) 
Naproxen RESS CO2 Up to 400 560-820nm (53) 
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bar 
26-327°C 
 
Phenytoin RESS-SC CO2 and 
menthol (co-
solvent 
96-196 bar 
45°C 
75-120nm (54) 
 
 
4.2.2. Supercritical Antisolvent (SAS) 
Supercritical fluids (SCFs) have gained significant attention in the last decade. SCFs have 
been used for processing of particles in the food, cosmetic and pharmaceutical industries 
(55).The technique uses the unique properties of supercritical fluids and is especially useful 
for those compounds which are insoluble in such fluids. In such cases, supercritical fluids act 
as an antisolvent and precipitate the drug from the drug solution (41). The method involves 
dissolving a drug in an organic solvent which is miscible with supercritical antisolvent to 
prepare a solution (16). The drug is then precipitated from solution either by adding 
supercritical antisolvent or drug solution into supercritical antisolvent (16, 41). In both cases, 
solvent diffuses into the antisolvent phase because of its miscibility with antisolvent and drug 
precipitation occurs due to low solubility into the SCF.  
Different types of nozzles are available to introduce the drug solution into SCFs including 
single or co-axial nozzles (41). The particle size obtained after precipitation of the drug 
depends on factors such as the type of solvent/antisolvent, volume ratio, concentration of 
drug in the solution, the degree of mixing, and the rate of antisolvent addition (16). In 
addition, factors such as temperature, pressure and diameter of the expansion nozzle also 
affect the final particle size. It has been reported that a smaller particle size can be obtained 
by using a narrow nozzle and by increasing the pressure and decreasing the temperature of 
the supercritical antisolvent (16). A number of antisolvent processes have been used for the 
production of nanoparticles including gas antisolvent (GAS) (56), aerosol solvent extraction 
system (ASES) (57), solution enhanced dispersion by supercritical fluids (SEDS) (58) and 
SAS with enhanced mass transfer (SAS-EM) (59). 
4.3. Solvent Removal Techniques 
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These techniques are based on removal of solvent. Conventional methods include spray-
drying and freeze-drying, however neither of these techniques can produce nanoparticles as 
more effective liquid atomization is required. Both techniques are used with improved 
atomization to achieve nanoparticles (16). 
4.3.1. Nano spray drying technique 
The Nano spray dryer B-90 was developed by Buchi Labortechnik AG, Switzerland (60). 
Figure 2 shows the structure of the nano spray dryer. This dryer has been designed to provide 
particle size within the range of 300nm to 5µm. The principle of the technique is that drying 
gas enters the drying chamber from the top and gets heated to the set inlet temperature. The 
piezodriven spray nozzle forms very fine droplets which are gently dried in the drying 
chamber. The dried particles are then collected on the collecting electrode (61). The drying 
gas exits the spray dryer from the bottom outlet after being filtered before leaving the dryer. 
Both the inlet and outlet temperatures are measured after heating and filtration (60). The 
ultra-fine droplets are generated through vibration technology. The piezoelectric actuator 
which is driven at an ultrasonic frequency of 60 KHz results in vibration of a stainless steel 
membrane or mesh (4.0 to 7.0 µm) and thus ejects ultra-fine droplets every second (61). The 
particles obtained by this method have a narrow particle size distribution (60).  
 
Figure 2. (a) Schematic diagram of Nano Spray Dryer (62), (b) Buchi Nano Spray Dryer B-
90 (61) 
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Recently, Venugopala et al. prepared nanocrystals of vildagliptin using the Buchi Nano Spray 
Dryer B-90. The nanosized drug particles obtained had a narrow size distribution with a 
particle size of 445 nm (63). In another study, the nano spray dryer B-90 was used to obtain 
sub-micron size particles of calpain inhibitor. The particles obtained were in the range of 300 
nm to submicron metre (62) 
4.3.2. Spray Freezing into Liquid (SFL) 
In this method, a solution containing drug and excipient is atomized into the cryogenic liquid 
which results in formation of frozen particles (64) that are then immediately collected and 
lyophilized. The process of atomization with rapid freezing results in the formation of 
amorphous nanoparticles with enhanced solubility and high surface area (64). Hu et al. 
prepared rapidly dissolving danazol powder with a diameter of 100 nm using this method. 
The particles were reported to have a very high surface area and solubility as 95% of danazol 
particles formed through the SFL process dissolved within 2 minutes (64). For large scale 
production by this method, the mixing step was modified using a 3-way nozzle i.e. different 
nozzles for solvent, antisolvent and atomizing air (65). The solvent and antisolvent are 
pumped into the nozzle through separate channels then mixed as soon as they leave the 
nozzle. The air, which is supplied by a third channel, facilitates the thorough mixing of 
solvent and antisolvent. The formed mixture enters into liquid nitrogen and is frozen at a 
faster rate than in the batch process (65). The particles obtained by this modified process have 
a smaller size and a higher dissolution rate (65).  
5. Top-Down Techniques 
Top-down techniques have become increasingly recognised by the pharmaceutical industry 
and there are currently a few marketed preparations which have been prepared by top-down 
techniques as shown in Table 3. Top-down techniques are high energy processes which are 
used to break down the particle size of drugs to the nanometre size range by application of 
friction. The two main top-down approaches are high pressure homogenization and media 
milling. These two techniques have been widely utilised by the pharmaceutical industry as 
they are easy to scale up to a commercial level and have also been accepted by regulatory 
authorities (5, 21, 66). 
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Table 3. Nanocrystals prepared by top-down techniques (19, 21, 23). 
Brand  
Name 
Active 
Ingredient 
Company Method Technology Administration 
route 
Rapamune
® 
Sirolimus Wyeth Top-down/WBM Nanocrystal
®
 Oral 
Emend
®
 Aprepitant Merck Top-down/WBM Nanocrystal
®
 Oral 
Tricor
®
 Fenofibrate Abbott Top-down/WBM Nanocrystal
®
 Oral 
Triglide
®
 Fenofibrate Skyepharma  Top-down/HPH IDD-P
® 
Oral 
Megace
®
ES Megestrol 
acetate 
Par  
Pharmaceuticals 
Top-down/WBM Nanocrystal
®
 Oral 
Invega
®
  
Sustenna 
®
 
Xeplion
®
 
Paliperidone 
palmitate 
Janssen Top-down/WBM Nanocrystal
®
 Parenteral 
 
5.1. Media Milling 
This technique was developed by Liversidge et al. in 1992 and is known as Nanocrystal® 
technology; it is regarded as one of the most successful nanosizing techniques (21, 67). 
Media milling techniques are the current versions of wet ball milling techniques. Wet ball 
milling techniques involve low energy ball milling in which a jar is filled with a milling 
medium and the drug dispersion in either aqueous or non-aqueous media is subjected to a 
milling operation (5, 21).  
The milling media used for wet ball milling is usually glass beads and these are moved by 
either electric stirrer or by movement of the whole jar. The liquid dispersion medium 
prevents adhesion and compaction of drug particles on the walls of the jar and also provides 
lubrication for the newly formed particles. Low energy ball milling usually takes a long time 
and cleavage of particles occurs through fracturing, cleavage and abrasion (21). The current 
Nanocrystal™ technology media milling technique involves high energy wet ball milling.  
High energy media milling requires suitable equipment and new media mills have been 
designed to meet the requirements of the pharmaceutical industry. These mills have high 
power densities so that production times can be reduced significantly and have the capacity to 
process up to 1000 kg of active ingredients per batch. In this process, the drug needs to be 
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exposed to high energy for 30 to 120 minutes which results in a high quality nanosuspension 
(2, 5, 12, 21). The media milling process is similar for small scale to commercial scale 
operations and can be operated in batch mode (discontinuous mode) or re-circulation mode 
(continuous mode).  
The commercial media milling process takes place in continuous mode and the media mills 
are equipped with media separators, which hold the milling medium within the milling 
chamber while the nanosuspension is in the circulation mode.  The suspension of poorly 
water soluble drug is added to the tank of the media milling chamber and, from this chamber, 
the suspension is pumped to the milling chamber where the particle size is reduced to 
nanometre size range by the fracturing, abrasion and cleavage mechanisms (2, 12, 21).  
The movement of balls in the milling chambers is initiated by a stirring device i.e. a central 
shaft with several discs, and rotates at a speed of 20,000 rpm or above (5). The residence time 
for achieving a particle size <200 nm varies from 30 to 120 minutes, depending on the 
properties of the compound and the extent of particle size reduction. As media milling is a 
continuous process, there is a screen at the exit of the milling chamber which separates the 
suspended, milled particles from the milling media. It has been reported that there is a 
grinding limit for drugs under a set of conditions such as milling speed, temperature and time, 
whereas the input of energy does not affect the particle size of drug (2).  
The media milling process requires special media and is selected on the basis of the inner 
surface of the milling chamber and the type of agitator used. Previously, glass beads or 
zirconium oxide beads were used but these resulted in contamination of the nanosuspension 
by abrasion with the milling chamber. Later, highly cross-linked polystyrene beads e.g. 
Pollymill® were introduced to minimise the contamination in the final nanosuspension. 
Pollymill® media of highly cross-linked polystyrene 0.5mm diameter beads (2, 5, 21) produce 
high quality nanosuspensions which are suitable for parenteral administration.  
Recently, the milling media used for the nanosization of drugs have been of much smaller 
dimensions i.e. <100 µm and centrifugal techniques have been used instead of conventional 
screens to separate the milling media from the milled product. The Ultra Apex Mill is an 
example of this type of machine where the centrifugal technique is used with media milling 
to separate the milling media and the milled product (5). A diagram of a media mill is shown 
in figure 3 below: 
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Figure 3. Schematic diagram of Wet Media Milling Process (68) 
Commercial equipment is available for both small scale and large scale production of 
nanocrystals. For example, agitated ball mills can be used for production of nanosuspensions 
of drug quantities as low as 10 mg. Commercial media milling equipment for large scale 
production is also available. The media milling process has produced smaller particles than 
other top-down techniques (21) It is, however, important to analyse the final nanosuspension 
for any impurities which may occur due to the milling chamber or milling media.  
The media milling process can be optimised by selecting the mediium so that it can withstand 
the process and by controlling process parameters such as milling time and shaft speed. The 
resultant nanosuspensions can be formulated into other dosage forms including tablets or 
powders. Such nanocrystal techniques have been accepted by regulatory agencies worldwide 
(2, 5). Table 4 shows examples of nanocrystals obtained by wet ball milling techniques. 
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Table 4. Nanocrystals prepared by wet media milling technique 
No. Drug Particle size 
obtained 
Milling 
Time 
Equipment used Reference 
1. Fenofibrate 150 nm 120 min Wet-stirred media mill 
(Netzsch Fine particle 
size technology, PA, 
USA) 
(69) 
2. Griseofulvin <100nm 64 minutes Microcer stirred media 
mill (Netzsch Fine 
particle size technology, 
PA, USA) 
(70) 
3. Bifendate 120 nm 45 minutes Mini-easy nano fine mil 
(Retch Topway 
Technology Co., 
Beijing, China) 
(71) 
4. Phenytoin 292 nm  90 minutes Oscillating beads-
milling apparatus 
(Multi-beads Shocker, 
Osaka, Japan) 
(72) 
5. Miconazole 140 nm 60 minutes High energy mill 
(Labstar LS1 Minicer, 
Netzsch, Germany) 
(73) 
6. Itraconazole 136 nm 60 minutes High energy mill 
(Labstar LS1 Minicer, 
Netzsch, Germany) 
(73) 
7. Naproxen 200 nm 240 minutes Netzsch media mill 
(NETZSCH, Blandon, 
PA) 
(74) 
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5.2. High Pressure Homogenization (HPH) 
This method for the production of nanosuspensions was patented by Muller et al. in 1994 and 
is considered the second most important technique for the production of drug nanocrystals 
(75). The HPH method employs two types of technique i.e. the microfluidization technique 
and Piston-gap homogenizers. The microfluidizer technique was developed by Skyepharma 
and it is known as the IDD-P™ technique i.e. insoluble drug delivery micro particle 
technology. This technique is based on the principle of jet-stream homogenization where the 
drug suspension is homogenized at high velocity and pressure by a homogenizing chamber.   
In this technique, two types of chambers are used i.e. the ‘Y’ type chamber and ‘Z’ type 
chamber. In the ‘Z’ chamber, the direction of flow of suspension changes which results in 
particle collision and shear forces and finally reduction in particle size. In the ‘Y’ type 
chamber, the suspension flows in two streams which collide with each other resulting in 
particle collision and the particles break because of shear and cavitation forces. It has been 
reported that due to the low power density of this system, 50 or more passes are required 
through the microfluidizer to obtain the required particle size. Thus, it is not regarded as a 
‘production friendly’ method (5, 21, 66). 
The piston-gap HPH technique developed by Muller et al. was termed Dissocubes™  and 
currently this trademark is owned by Sky Pharma. A second variant of piston-gap HPH was 
developed in 1999 and is known as Nanopure® technique and it is owned by Pharmasol 
GmbH/Berlin. The technique involves homogenization of drugs in either a medium without 
water or with a reduced water content e.g. a mixture of water with PEG.  
5.2.1. Dissocubes Homogenization Technique 
In this technique, the drug is mixed in an aqueous solution of surfactant and stabilizers and 
the resulting dispersion is passed through a narrow gap (diameter 25 um) in the homogenizer 
with a very high velocity and a very high pressure of 500 to 1500 bars. Before entering the 
narrow gap, the dispersion is present in a cylinder which has a diameter of about 3 cm (5, 21, 
66, 76). The suspension of drug is passed through the homogenizer repeatedly to achieve the 
desired particle size and pressure is increased from 500 bar to 1500 bar in a stepwise manner. 
As the width of the gap is very narrow i.e. a few micrometres, it is recommended that the 
starting material is pre-micronized using fluid energy milling to prevent clogging in the gap 
and to reduce milling time (21).  
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When the drug mixture is contained in a closed system, the pressure is constant but as soon as 
the mixture passes through a narrow gap, an increase in the dynamic pressure of the liquid 
develops and the static pressure of the liquid in the gap falls below the vapour pressure which  
results in boiling of the liquid and formation of bubbles. As soon as the mixture leaves the 
homogenization gap, the gas bubbles collapse due to the normal pressure conditions and drug 
particles of nanometre size range are achieved by cavitation forces (which are generated 
because of formation and collapse of gas bubbles), shear forces and collision.  
The quality of the resultant drug particles depends on various parameters including  the 
power density of the system, the number of homogenization cycles, the hardness of the drug, 
and temperature (5, 76). HPH  can be used for both laboratory and commercial applications 
as it is a scalable process. HPH does not generate impurities due to abrasion or cleavage thus, 
it can be used to produce parenteral nanosuspensions. In addition, the latest homogenizers 
have ceramic valves which can produce nanosuspensions without impurities even if there are 
harsh processing conditions (21). Figure 4 shows a schematic diagram of a high pressure 
homogenizer. 
 
Figure 4. Schematic diagram of high pressure homogenizer (77) 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
5.2.2. Nanopure® Technology 
The most important feature of this technique is that the process can take place a in non-
aqueous phase (e.g. polyethylene glycol) or a reduced water phase (water-alcohol mixtures), 
thus it is suitable for reducing the particle size of thermolabile drugs and drugs which 
undergo hydrolysis. It is also used when nanosuspensions are converted into solid dosage 
forms such as tablets since less heat will be required for removing solvent from the system as 
compared to homogenization with water. In this method, drug powder is mixed in a non-
aqueous medium or a reduced-water mixture as described above and the resulting suspension 
is homogenized in a piston-gap homogenizer. This type of homogenization is performed at 
low temperatures e.g. at 0°C and below freezing point e.g. -20°C. It was found that 
homogenization was more effective at low temperatures. The shear forces of the turbulent 
flow help to break down the drug particles to the nanometre size range (5, 76, 78).  
Recently, supercritical CO2 has been utilized  as a dispersion medium in the homogenization 
of ketoprofen and phenytoin (5). Nanopure technology is available commercially for lab scale 
as well as commercial scale production e.g. Micron Lab 40 is a machine used by PharmaSol, 
GmbH, Germany. The homogenizer allows pressure to vary from 100 bars to 1500 bars and it 
also contains a temperature-controlled jacket which maintains the temperature at 0°C or 
below and can be used for 40 ml samples. A homogenizer used for a large scale production 
by the pharmaceutical industry is the Rannie 118; it can process materials up to 1200 L per 
hour at a pressure of 1500 bar (78). Table 5 shows examples of drug nanocrystals which have 
been produced by high pressure homogenization. 
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Table 5. Examples of drug nanocrystals obtained by high pressure homogenization 
No. API Particle 
size 
Operating 
Conditions 
Equipment used Reference 
1. Quercetin 338.3 nm 2 cycles at 300 
bar, 2 cycles at 
500 bar, 
1 cycle at 1000 bar 
and 20 cycles at 
1500 bar 
LAB 40 high 
pressure 
homogenizer (APV 
Deutschland GmbH, 
Unna, Germany) 
(79) 
2. Atorvastatin 215.3± 
14.2 nm 
1-3 cycles at 1378 
bar to 2757.9 bars 
High-pressure 
homogenizer (Nano 
DeBEE, BEE 
International Inc., 
MA, USA) 
(80) 
3. Budesonide 640 nm 60 cycles at 1000 
bar 
High pressure 
homogenizer 
(AH110D, ATS 
Engineering, Italy) 
(81) 
4. Itraconazole 267.6±15.8 
nm 
2 cycles at 150 
bar, 2 cycles at 
500 bar, 2 cycles 
at 1000 bar and 15 
cycles at 1350 bar 
AH100D high 
pressure 
homogenizer (ATS 
Engineering Inc., 
China) 
(82) 
5. Herpetrione 286±1.3 
nm 
5 cycles at 500 bar 
and 20 cycles at 
1000 bar 
High shear 
homogenizer (Ultra-
Turrax T25, IKA, 
Germany) 
(83) 
6. Nimodipine 450nm 2 cycles at 200 
bar, 5 cycles at 
500 bar then 15-20 
cycles at 1500 bar 
Niro-soavi 
NS1001L (ATS Co. 
Ltd., Italy) 
(84) 
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6. Combination Techniques 
Various combinations of precipitation techniques and high energy processes have been used 
to prepare drug nanoparticles. Using these combination approaches, significant reductions in 
processing times can be achieved by subjecting the drug to precipitation  before processing 
through a top-down process (21). These techniques also help to achieve a better size 
reduction as compared to conventional techniques. The first combination approach was 
developed by Baxter and named Nanoedge™  technology (21, 67) The technique involved 
precipitation of a drug and then an annealing step is performed by application of high energy 
e.g. HPH. Annealing is a process of converting thermodynamically unstable matter into a 
stable form by applying stress followed by thermal relaxation (67). Combination techniques 
currently used include Nanoedge™ , H69, H42, H96 and the CT combination technique (85) 
6.1. Nanoedge™ Technology 
Nanoedge technology is a combination of a micro-precipitation technique followed by a top-
down technique such as high pressure homogenization (HPH). The drug is dissolved into an 
organic solvent (miscible with antisolvent) to form a solution which is then mixed with an 
antisolvent such as water. As the drug has the least solubility in water, the solvent quickly 
diffuses into the antisolvent causing the drug to  precipitate. This step is a pre-treatment step 
and the amorphous or crystalline drug particles obtained by this method are subjected to HPH 
to make them thermodynamically stable by annealing (85). This technique has been used for 
production of the anti-cancer drug paclitaxel with improved solubility and small particle size 
(1000 nm) (85), and for formulation of itraconazole and isradipine nanosuspensions (16). The 
technique has also been used for preparation of ultrafine particles of beclomethasone 
dipropionate with a size range of 200 to 300 nm. It was found that aerosol performance was 
improved with the modified nanosized formulation as compared with original  
beclomethasone dipropionate (86). 
6.2. H69 technology 
This technology was developed by Muller and Moschwitzer and is a combination of the 
microprecipitation technique with HPH. It differs from the Nanoedge technique as cavitation 
occurs at the same time as particle formation (85). In this method, addition of antisolvent to 
drug solution is carried out in a controlled manner by using an infuser device. The 
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disadvantages of the H69 and Nanoedge techniques are similar as nanosuspensions prepared 
by both methods produce organic solvent residues which need to be further removed (85). 
6.3. H42 technology 
This technique was also developed by Moscwitzer (16) and involves a combination of spray-
drying precipitation followed by HPH technique (87). The spray-drying process is a pre-
treatment step which provides solvent free and fine drug particles which are further treated by 
the HPH process. Due to the nature of fine particles produced by spray-drying, the risk of 
clogging of the homogenizer is reduced (87). The H42 process has been used to obtain 
glibenclamide nanoparticles of particle size of about 236 nm (87). It has also been used for 
the production of nanoparticles of reseveratrol of mean particle size of 200 nm (85). 
6.4. H96 technique 
This techniques is used for production of nanosuspensions and involves freeze-drying as a 
pre-treatment step followed by high pressure homogenization. The precipitated drug particles 
are frozen by liquid nitrogen then freeze dried (85).  The freeze-drying process eliminates the 
use of organic solvent and is optimised to produce brittle particles so that further processing 
with HPH yields a very small particle size. This technique has been used for the preparation 
of nanosuspensions of amphotericin B with a mean particle size of 100 nm (85). 
6.5. Combination Technology (CT) 
This is a combination of top-down techniques i.e. pearl milling and the high pressure 
homogenization process (88). The pre-treatment step is pearl milling of a macrosuspension 
followed by homogenization through HPH. The treatment with HPH provides physical 
stability to nanosuspensions by avoiding the Ostwald ripening phenomenon (85). The CT 
technique has been used for the processing of hesperidine nanosuspensions and a particle size 
of 599 nm was reported along with long term stability (85). 
7. Stabilization of nanosuspensions 
The nanosuspensions prepared by the methods described above offer many advantages such 
as improved drug bioavailability, high drug loading, reduced side effects , reduced dose and 
increase in patient compliance (18). Nanosuspensions reduce the risk of side effects  as a 
lesser number of excipients are required for the formulation. Unfortunately, nanosuspensions 
can be unstable due to particle growth and nucleation. This is because nanosuspensions are 
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thermodynamically unstable due to their high surface area and the positive Gibbs free energy 
associated with a high surface area (18, 22).  
7.1. Thermodynamically unstable nanosuspensions try to minimize the energy associated 
with the system by an agglomeration process (22). It has been found that the 
activation energy of the system plays an important part in the agglomeration process 
and stabilizing a nanosuspension can prevent the process by increasing the activation 
energy of the system (22). Therefore, addition of a suitable stabilizer to a 
nanosuspension is important to prevent aggregation of particles. Stabilizers induce 
ionic or steric stabilization by covering the surface of particles (89). Steric 
stabilization can be achieved by adsorbing the stabilizing polymer on the surface of 
drug particles and electrostatic stabilization can take place by adsorption of charged 
molecules or ions of stabilizing polymer or surfactant onto the surface of drug 
particles (90). . Examples of stabilizers  
The stabilizers commonly used in the formation of nanosuspensions include polymers such as 
hydroxypropyl methyl cellulose (HPMC) (22), hydroxypropyl cellulose (91), polyethylene 
glycols (PEGs) (18), D-α-tocopherol polyethylene glycol succinate (92), polyvinyl alcohols 
(18), ionic surfactants like sodium lauryl sulfate (18), chitosan polymer (93) and non-ionic 
surfactants e.g. tweens (18). Ionic surfactants provide stabilization to nanosuspensions by 
electrostatic repulsion and polymers and non-ionic surfactants provide stabilization through 
steric repulsion. Some food proteins including soybean protein isolate and whey protein 
isolate have also been used as stabilizers. For example, He et al. prepared indomethacin 
nanosuspension using food proteins as stabilizers (18). 
8. Conversion of a nanosuspension into solid products 
Nanosuspensions can be stabilized using suitable stabilizers but their prolonged storage is 
associated with chemical instability resulting in their hydrolysis, chemical reactivity of the 
drug, or leakage of the drug. Conversion of a nanosuspension into a solid product can 
stabilize the product both physically and chemically. (22, 90). Freeze-drying and spray-
drying processes have been used to transform nanosuspensions into dry powders. The dry 
powder can be further filled in capsules or compressed into tablets. However, the flow 
properties of the powder obtained by drying processes may change, resulting in poor flow, 
high bulk density and hygroscopicity. Suitable excipients are added to such powders to 
improve their flow properties.  
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In addition to spray-drying and freeze-drying, spray granulation and palletisation processes 
have also been used for obtaining dry powders (22). Rapid dissolution and disintegration are 
considered important parameters of solid dosage forms and both should be monitored while 
converting a nanosuspension into a solid dosage form. The dissolution potential of 
nanocrystals can be preserved by addition of matrix formers such as sucrose, lactose, 
mannitol and sorbitol before the drying step (94). Sucrose has been found to be a suitable 
matrix former and was found to enhance the dissolution rate of loviride nanocrystals when 
converted into a solid dosage form. Some examples of nanosuspensions dried by the above 
mentioned processes are shown in table 6 below: 
Table 6.  Examples of nanosuspensions dried by freeze-drying and spray-drying techniques. 
No API Drying 
Technique 
Matrix used reference 
1. Itraconazole Spray-drying Mannitol (73) 
2. Piroxicam Freeze-drying Mannitol (95) 
3. Nifedipine Freeze-drying Sucrose, 
maltose, 
glucose 
(96) 
4. Naproxen Freeze-drying None (22) 
5. Budesonide Spray-, freeze-
drying 
Mannitol (97) 
 
9. Case Studies 
9.1. Nanosizing of sodium ibuprofen by the Bottom-down technique (SAS method) 
(55) 
Mezzomo et al. 2015 produced nanosized ibuprofen sodium by the solvent-antisolvent 
method (SAS). Ibuprofen sodium was dissolved in acetone (solvent) by application of heat 
(40°C, 10 minutes) and agitation until ibuprofen was completely solubilized in acetone. The 
supercritical antisolvent used in the process was 99.9% pure CO2 which was delivered as  a 
liquid using a heat exchanger and at a pressure of 60 bar. A supercritical fluid extraction unit 
was used for the extraction of sodium ibuprofen and a pump was used to provide the desired 
pressure to the solvent and antisolvent. To start the experiment, pure carbon dioxide was 
pumped into the precipitator vessel and once the desired experimental conditions such as 
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temperature, pressure and flow rate  of supercritical solvent were achieved, the drug solution 
was fed into the precipitator unit. Precipitated particles were stored at -10°C and were also 
protected from light.  
The effect of temperature, pressure, solution flow rate and concentration of feed solution on 
precipitation of ibuprofen was evaluated at a constant flow rate of CO2 i.e. 1 kg carbon 
dioxide per hour. The pressure ranged from 80 to 140 bar, temperature from 35 to 55°C, the 
solution flow rate was 1 to 3ml/min, and the concentration of feed solution varied from 0.5 to 
1.5mg/ml. The resulting particles were evaluated in terms of morphology, size and degree of 
crystallinity using scanning electron microscopy (SEM), differential scanning calorimetry 
(DSC ), Powder X-ray diffraction, and RAMAN spectroscopy. The results obtained by the 
SAS method were also compared with the results obtained by a conventional lyophilisation 
technique. 
Phase equilibrium data showed that at 40°C ibuprofen was completely dissolved in acetone 
and addition of supercritical solvent to the drug solution resulted in the precipitation of 
ibuprofen at 35 to 45°C. From this experiment, it was concluded that CO2 acts as an 
antisolvent and solubility of ibuprofen increases with an increase in temperature. Moreover, 
the morphology of precipitated ibuprofen was studied and compared with ibuprofen obtained 
by different operational conditions as well as the lyophilized samples and un-processed 
samples of sodium ibuprofen. It was observed that particle size of sodium ibuprofen was 
reduced to the nanometre size range (from 144±87µm to380±84 nm) by the SAS method. 
Moreover, the results obtained for lyophilized samples were smaller in size (126±25 µm) 
than unprocessed ibuprofen.  
Overall, it was concluded from this experiment that nanoparticles of ibuprofen can be 
obtained by the SAS method using CO2 as antisolvent. The particle size of ibuprofen was in 
the range of 380±84nm at all conditions of the experiment. However, the best operating 
conditions were found to be: Pressure 110 bar, temperature 35°C, concentration of ibuprofen 
0.5mg/ml, flow rate 1ml solution/minute, and 1kg CO2/hour. By reducing the ibuprofen 
particle size to the nanometre size range, the surface area can be increased and bioavailability 
can be improved significantly. Thus, the SAS method for the production of nanoparticles of 
ibuprofen was considered to be successful. 
9.2. Fabrication of quercetin nanocrystals: Comparison of different methods  (79) 
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Kakran et al (2012) studied different methods for fabrication of quercetin nanocrystals using  
HPH, bead milling and cavi-precipitation techniques (H69 techniques). The aim of the 
experiment was to compare the production efficiency, particle size and quality of products 
obtained. Quercetin is an antioxidant and several benefits of this compound have been 
reported such as protection against osteoporosis, some cancers, cardiovascular diseases, 
pulmonary diseases and ageing. This compound has been reported to have extremely low 
bioavailability (around 1%) in humans due to its poor solubility and high protein binding. 
Therefore, nanocrystals of the drug were prepared to improve its solubility and dissolution. 
High Pressure Homogenization of 5% and 10% w/w quercetin suspension was performed 
using a LAB 40 homogenizer to produce a nanosuspension with a batch size of 40 ml. 
Nanosuspensions were made in ultra-purified water using tween 80 as a stabilizer (1% w/w 
and 2% w/w). Initially, a premilling step was conducted by increasing pressure (2 cycles at 
300 bar and 500 bar each and then 1 cycle at 1000 bar). This was followed by HPH at 1500 
bars for 20 cycles. In addition, another batch of samples was prepared at low pressure of 500 
bar with 20 cycles. Samples were also collected after pre-milling and after certain 
homogenization cycles i.e. at 1, 5, 10, 15 and 20 cycles. 
Another aqueous nanosuspension of quercetin was prepared by using a bead mill in a 
continuous mode. The milling medium used for the process was zirconia beads of size 0.4-
0.6mm and 0.2mm. The milling chamber had a capacity of 200 ml and was filled with 150 ml 
of milling media and then 50 ml of quercetin suspension with 5 % and 10% quercetin. The 
nanosuspension was stabilized using tween 80 (1% and 2% w/w). The suspension was milled 
in the milling chamber for 90 minutes at a speed of 2000 rpm. Samples were collected at 
regular intervals during the milling process i.e. after 5, 30, 60 and 90 minutes. 
In another experiment, a suspension of quercetin was prepared using the cavi-precipitation 
technique. In this method, DMSO and ethanol were used as solvents and 100 ml aqueous 
solution of tween 80 was used as the antisolvent. Quercetin solutions were prepared by 
dissolving in 20 ml DMSO and 50 ml ethanol. The solution was pumped at a rate of 1ml/min 
via an injection pump into the micro-fluidizer which contains antisolvent. The resulting 
nanosuspension was homogenized at 500 bar. 
The nanosuspensions obtained by the above experiments were subjected to particle size 
analysis using photon correlation spectroscopy (PCS) and laser diffractometry. PCS was used 
to determine the mean particle size and polydispersity index (PDI). PDI gives an indication of 
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the size distribution of the samples. PDI values from 0.1 to 0.2 indicate a narrow particle size 
distribution, but PDI value of 0.5 indicates a broad distribution of particles. Laser diffraction 
was used for measurement of larger particles i.e. up to 2000µm. The morphology of particles 
was studied by field emission scanning electron microscopy. A solubility test of quercetin 
was undertaken in ultra-purified water (milli-Q water) in a water bath at a temperature of 
25°C. Dissolution tests for quercetin were performed by using a USP II rotating paddle 
apparatus at a temperature of 37°C.  
It was observed that as the number of homogenization cycles increased the particle size of   
of quercetin decreased with 20 cycles found to be optimal. Moreover, the particle size 
reduced with increased  pressure, e.g. the particle size almost halved when pressure was 
increased from 500 bar to 1500 bar. The particle size of 5% and 10% w/w quercetin 
suspensions were 338.3 nm and 442 nm respectively.  
There was no significant difference in the particle size of quercetin nanosuspensions obtained 
by using 0.2 mm and 0.4-0.6 mm beads for milling. The particle size obtained by using the 
smaller beads was slightly higher which suggests that decreasing the size of milling beads 
does not always result in greater particle size reduction. After 60 minutes of milling time 
using 0.4-0.6 mm milling beads, the average particle size obtained for 5% and 10% 
formulations were 253.2 nm and 270.7 nm respectively. Increasing milling time by an 
additional 30 minutes produced an increase in particle size due to an increase in kinetic 
energy of the particles which then resulted in particle aggregation.  
The results obtained using the Cavi-precipitation process revealed that the particle size 
obtained with DMSO was 469.7 nm and the PDI was 0.111. The smallest particle size 
obtained using ethanol as solvent was 559.4 nm with a PDI of 0.180. The solubility study 
results showed a significant increase in the saturation solubility of quercetin nanocrystals as 
compared to the coarse quercetin powder. The saturation solubility of quercetin increased by 
9 times, to 25.59±1.11 µg/ml for nanosuspensions as compared to coarse nanosuspensions 
which had a saturation solubility of 2.84 ±0.03 µg/ml. It was also found that samples 
prepared using ethanol showed very high solubility during the cavi-precipitation process and 
could be used in the final formulations. 
The dissolution rate of quercetin nanocrystals was higher than for coarse quercetin. Complete 
dissolution for nanosuspensions obtained by the milling method occurred in 120 minutes. 
However, 70% dissolution was observed for nanosuspensions prepared by the 
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homogenization process at 500 bar, and only 10% dissolution for coarse quercetin 
microsuspension.  
Comparing the samples obtained by the three different size reduction methods used in the 
study revealed that the maximum particle size reduction was obtained by the bead milling 
process, followed by HPH and then cavi-precipitation. The smallest size of quercetin 
obtained by the bead milling process was around 276.7 nm with a saturation solubility of 
25.59± 1.11 µg/ml. The particle size of quercetin obtained by cavi-precipitation process was 
higher compared to other two processes. 
10. Conclusion 
The concept of nanosizing of poorly-soluble drugs to improve bioavailability has been widely 
accepted by the pharmaceutical industry and regulatory authorities. However, to date, 
relatively few preparations of drug nanocrystals have been marketed. This may be set to 
increase as there have been many advances in nanosizing technologies in recent years. 
Challenges with top-down techniques such as long milling times and abrasion issues have 
been resolved. Issues with bottom-up techniques including agglomeration, stabilization, 
residual solvent content and other process parameters to obtain nanosized particles are 
currently being studied and resolved. Recently, combination techniques have gained lot of 
attention and show promise in overcoming problems associated with individual drugs and 
single techniques. The literature indicates that there is continuous improvement in all of these 
techniques and more drugs with solubility issues are being considered for nanosizing. 
Moreover, with a better understanding of the biopharmaceutical characteristics of drugs, it is 
easier to select the best candidates for nanosizing. It is now evident from the DCS 
classification that compounds which show dissolution rate-limited bioavailability are 
potentially the best candidates for nanosizing. 
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